Biomarkers of VTE risk can be detected in blood (Illustration: MostPhotos.com)
Currently, there are no well-reognized predictive biomarkers incorporated into clinical practice that can identify those at high risk of first and recurrent VTE. By using targeted plasma proteome data from a large nested case-control study derived from the Tromsø study, we will identify biomarkers that are associated with risk of future VTE. We will perform protein quantitative loci (pQTL) analysis to identify genes that regulate biomarker levels, and assess potential causal associations between biomarkers and VTE by performing two-way Mendelian Randomization studies (using genetic data from the INVENT-consortium). Further, we will investigate the interaction between blood cell variables and biomarkers.
Principal Investigator: John-Bjarne Hansen
External collaborators: Pål Aukrust (Oslo University Hospital), Nicholas L Smith (University of Washington/INVENT consortium)